Literature DB >> 11549290

MAPK and Akt act cooperatively but independently on hypoxia inducible factor-1alpha in rasV12 upregulation of VEGF.

A Sodhi1, S Montaner, H Miyazaki, J S Gutkind.   

Abstract

Oncogenic ras upregulates the expression of VEGF through the activation of the transcriptional enhancer hypoxia inducible factor-1alpha (HIF-1alpha) by a still poorly understood mechanism. Here, we demonstrate that both the Raf/MEK/MAPK and the PI3 kinase/Akt signaling pathways potently and additively stimulate the expression from a hypoxia response element (HRE) within the 5'flanking region of the VEGF promoter. Interestingly, while MAPK appears to specifically upregulate the transactivation activity of HIF-1alpha through direct phosphorylation of its regulatory/inhibitory domain, GSK-3, a downstream target of Akt, directly phosphorylates the HIF-1alpha oxygen-dependent degradation domain. These results suggest a novel mechanism whereby two divergent signaling pathways emerging from Ras may cooperatively but independently regulate the activity of a HIF-1alpha, thereby promoting the expression of a potent angiogenic mediator.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11549290     DOI: 10.1006/bbrc.2001.5532

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  37 in total

1.  Kinase suppressor of ras 1 (KSR1) regulates PGC1α and estrogen-related receptor α to promote oncogenic Ras-dependent anchorage-independent growth.

Authors:  Kurt W Fisher; Binita Das; Robert L Kortum; Oleg V Chaika; Robert E Lewis
Journal:  Mol Cell Biol       Date:  2011-04-25       Impact factor: 4.272

Review 2.  Gut mucosal healing: is the science relevant?

Authors:  Marc D Basson
Journal:  Am J Pathol       Date:  2002-10       Impact factor: 4.307

3.  1α, 25-Dihydroxyvitamin D regulates hypoxia-inducible factor-1α in untransformed and Harvey-ras transfected breast epithelial cells.

Authors:  Yan Jiang; Wei Zheng; Dorothy Teegarden
Journal:  Cancer Lett       Date:  2010-07-23       Impact factor: 8.679

4.  Physical and functional interactions between Runx2 and HIF-1α induce vascular endothelial growth factor gene expression.

Authors:  Tae-Geon Kwon; Xiang Zhao; Qian Yang; Yan Li; Chunxi Ge; Guisheng Zhao; Renny T Franceschi
Journal:  J Cell Biochem       Date:  2011-12       Impact factor: 4.429

5.  Artemisinin induces doxorubicin resistance in human colon cancer cells via calcium-dependent activation of HIF-1alpha and P-glycoprotein overexpression.

Authors:  C Riganti; S Doublier; D Viarisio; E Miraglia; G Pescarmona; D Ghigo; A Bosia
Journal:  Br J Pharmacol       Date:  2009-03-09       Impact factor: 8.739

6.  Constitutive and oxidative-stress-induced expression of VEGF in the RPE are differently regulated by different Mitogen-activated protein kinases.

Authors:  Alexa Klettner; Johann Roider
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2009-07-15       Impact factor: 3.117

7.  Hypoxia activates the K-ras proto-oncogene to stimulate angiogenesis and inhibit apoptosis in colon cancer cells.

Authors:  Min Zeng; Hirotoshi Kikuchi; Maria S Pino; Daniel C Chung
Journal:  PLoS One       Date:  2010-06-04       Impact factor: 3.240

8.  TNFalpha induces HIF-1alpha expression through activation of IKKbeta.

Authors:  Hsu-Ping Kuo; Dung-Fang Lee; Weiya Xia; Yongkun Wei; Mien-Chie Hung
Journal:  Biochem Biophys Res Commun       Date:  2009-09-17       Impact factor: 3.575

9.  Inactivation of PTEN is associated with increased angiogenesis and VEGF overexpression in gastric cancer.

Authors:  Ye-Jiang Zhou; Yu-Xia Xiong; Xiao-Ting Wu; De Shi; Wei Fan; Tong Zhou; Yue-Chun Li; Xiong Huang
Journal:  World J Gastroenterol       Date:  2004-11-01       Impact factor: 5.742

10.  Kinome siRNA screen identifies SMG-1 as a negative regulator of hypoxia-inducible factor-1alpha in hypoxia.

Authors:  Run-Qiang Chen; Qing-Kai Yang; Yan-Ling Chen; Vasco A Oliveira; William S Dalton; Colleen Fearns; Jiing-Dwan Lee
Journal:  J Biol Chem       Date:  2009-04-30       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.